|Articles|September 14, 2021
- Pharmaceutical Executive-09-01-2021
- Volume 41
- Issue 9
Pharmaceutical Executive, September 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 4 years ago
When Innovation Outpaces HTA, Access Struggles to Keep Upabout 4 years ago
Doubling Down On Innovation, Recoveryabout 4 years ago
Developing a Product Launch Strategy for an Orphan Drugabout 4 years ago
Investing for Success: Finding the Right Launch Balanceabout 4 years ago
Rethinking Obesity: Wegovyabout 4 years ago
Fear Factor: Palforziaabout 4 years ago
Formidable Option: Orgovyxabout 4 years ago
No Small Feat: Nurtec ODTabout 4 years ago
‘Rare’ Reinforcement: Evrysdiabout 4 years ago
Serial Problem SolverNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Is FDA Streamlining Regulations in the Biosimilar Space?
2
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
3
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
